Free tool
FAERS Monitor: Unituxin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125516 or its brand name (Unituxin, Dinutuximab). Reports on generic versions are filed under their own applications.
Reports
859
Serious
757
88% of reports
Hospitalization
300
Death reported
173
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pyrexia172
- off label use116
- pain90
- neuroblastoma recurrent89
- abdominal pain80
- vomiting68
- aspartate aminotransferase increased64
- alanine aminotransferase increased62
- hypotension59
- anaemia58
- neuroblastoma56
- hypoalbuminaemia55
- nausea52
- pain in extremity51
- diarrhoea50
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 10 |
| 2016 | 24 |
| 2017 | 62 |
| 2018 | 82 |
| 2019 | 62 |
| 2020 | 72 |
| 2021 | 138 |
| 2022 | 106 |
| 2023 | 102 |
| 2024 | 68 |
| 2025 | 61 |
| 2026 | 72 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,300 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| neuroblastoma recurrentSignal | 89 | 19134.3 | 14620.5 | 945,531 |
| neuroblastomaSignal | 56 | 4197.3 | 3186.7 | 197,021 |
| hypoalbuminaemiaSignal | 55 | 174.5 | 135.0 | 9,255 |
| aspartate aminotransferase increasedSignal | 64 | 29.5 | 23.3 | 1,739 |
| alanine aminotransferase increasedSignal | 62 | 24.8 | 19.5 | 1,392 |
| pyrexiaSignal | 172 | 12.2 | 10.7 | 1,782 |
| abdominal painSignal | 80 | 8.4 | 6.8 | 522 |
| anaemiaSignal | 58 | 7.4 | 5.8 | 320 |
| hypotensionSignal | 59 | 7.2 | 5.6 | 312 |
| pain in extremitySignal | 51 | 4.2 | 3.2 | 125 |
| painSignal | 90 | 3.6 | 3.0 | 170 |
| vomitingSignal | 68 | 3.5 | 2.8 | 124 |
| off label useSignal | 116 | 3.2 | 2.7 | 186 |
| diarrhoea | 50 | 1.9 | 1.4 | 21 |
| nausea | 52 | 1.6 | 1.2 | 12 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.